SINGAPORE TRADE ACCELERATOR
Trade accelerator: FAQs
The Trade Accelerator is a structured, six-month, outcomes-driven internationalisation programme developed by the British Chambers of Commerce to support UK SMEs in entering global markets. It is designed as a scalable platform, with sector-specific cohorts tailored to strategic growth industries and based on demand of UK SMEs.
The inaugural cohort focuses on Singapore Life Sciences, targeting opportunities within Singapore’s fast-growing and globally connected biomedical ecosystem.
The Singapore Life Sciences programme runs over six months but does not require full-time participation. It comprises a series of workshop-led sessions held at least twice per month, alongside mentoring, advisory and market engagement activities. The duration of each session varies depending on the module and subject matter.
Future cohorts will expand to additional sectors and priority markets as part of a broader international trade acceleration series and based on demand from UK SMEs
Singapore has emerged as one of the fastest-growing and most globally connected life sciences hubs. Its ecosystem now includes a vibrant mix of MNCs, SMEs and startups across the biomedical sciences industry with 30+ pharmaceutical multinationals, 60+ biotech companies, 50+ medtech multinational headquarters and over 400 medtech and digital health start-ups, supported by world-class research institutions, incubators and funding bodies[1].
Singapore’s strategic positioning, trusted regulatory environment, strong IP protection, and deep innovation networks make it an ideal launchpad to Southeast Asia and beyond. For UK life sciences companies seeking export success, Singapore offers both the infrastructure and the market access to turn early commercial traction into regional growth.
Singapore seeks Life Sciences companies with product validation, regulatory readiness and ability to align to the local system. Singapore also offers a regional manufacturing and supply chain base, a translational research hub, and serve as a regulatory reference landscape for Southeast Asia.
Singapore’s recently released Research, Innovation and Enterprise (RIE) 20301 highlights Singapore’s health priorities in the areas of healthy aging, precision medicine, and sustainable healthcare. These include biologics and advanced therapeutics, translational medicine and clinical research, medtech and digital health integration, and advanced manufacturing and supply chain resilience.
Who is the programme for?
The programme is designed for small and medium-sized UK life sciences businesses developing innovative health products and technologies, including those operating in:
- Medical technology (MedTech), including medical devices and equipment
- Diagnostics and In Vitro Diagnostics (IVD)
- Digital health and software as a medical device (SaMD)
- Biopharmaceuticals and therapeutics
The accelerator is intended for companies with a defined product or platform seeking practical, commercially focused support to enter international healthcare markets. It is particularly suited to firms looking to secure customers, navigate regulatory pathways, build clinical credibility, and establish strategic partnerships in Singapore and the wider Southeast Asian region.
Based on insight from the British Chambers of Commerce, SMEs often struggle with:
- Finding trusted in-market partners
- Fragmented or generic export support
- High commercial and operational risk
- Limited clarity on real market demand
- Weak follow up after trade missions
- Gaps in commercial or operational readiness
The Trade Accelerator seeks to provide a structured answer to these challenges.
Participants gain:
- Expert-led capability building
- Market and regulatory insight
- Advice on market fitand potential partners
- A one-week trade mission to Singapore
- Post-mission support to convert opportunities into deals
Additionally, the Trade Accelerator modules will address common Life Sciences market entry queries into Singapore such as (non-exhaustive):
Regulatory Landscape
- How does Singapore’s regulatory framework differ from the UK MHRA and EU systems?
- Can products approved by MHRA, US FDA and EU system have an accelerated pathway into Singapore?
- What evidence or clinical data is typically required for market entry in Singapore?
- What are realistic regulatory timelines for medtech, diagnostics, or therapeutics?
Clinical Adoption Landscape
- What level of clinical validation is expected before hospitals adopt new technologies?
- How important are local clinical champions in Singapore?
- How can UK companies run pilot programmes with hospitals in Singapore?
Commercialisation Landscape
- Who are the key buyers in Singapore’s healthcare system (public hospitals, private providers, insurers)?
- How does procurement work across Singapore’s public healthcare clusters?
- What pricing and reimbursement models are most successful in the region?
Partnerships
- How do companies secure R&D or commercial partnerships with local research institutions?
- What are the common funding pathways for companies entering Singapore?
- How do UK companies structure joint ventures or strategic partnerships in Singapore and Southeast Asia?
Scaling Across Southeast Asia
- How different are regulatory and procurement processes across ASEAN countries?
- How does Singapore function as a gateway to Southeast Asian healthcare markets?
- What operational capabilities are required to support regional expansion?
The Trade Accelerator is outcomes-driven. Success is measured against tangible commercial, regulatory, and market access milestones. The success indicators include:
- Advancing investment discussions linked to international expansion
- Establishing distribution, clinical, or R&D partnerships
- Progressing regulatory submissions or approvals
- Demonstrating measurable productivity, cost, or patient impact to clients
- Generating export revenue within a reasonable time frame of programme completion
- Building a validated international sales pipeline
- Ability to secure international customers or pilot deployments
Stage 1 – 9 March 2026: Programme Launch: webinar
Stage 2 – 9 March – 31st March 2026: Applications open
Stage 3 – April 2026: Shortlisting and Eligibility Review
Stage 4 – w/c 27 April 2026: Cohort Confirmation and Pre–Start Onboarding
Stage 5 – Mid–May – In Person Cohort Kick Off in Central London
Includes:
- Two-day workshop (approx.): Day 1: 12:00-17:00 and Day 2: 09:00-14:00
Stage 6 – Virtual Training Modules – around 19 virtual training modules, from 30min to morning sessions. Typically, weekly.
Stage 7 – Mid–May – mid September: Mentoring and Coaching & Trade Mission Preparation
Stage 8 – Week commencing 7th September: One Week Trade Delegation to Singapore including:
- Training modules,
- Site visits
- Networking
- Attendance to the Medical Fair Asia
Stage 9 – 19 October: Post Mission Follow Up and Evaluation
Each participating company may nominate up to two or three representatives to take part in the Trade Accelerator programme. We encourage companies to appoint a consistent core team to ensure continuity, although representatives may rotate between sessions where appropriate.
The programme runs over a six-month period but does not require full-time participation. It is delivered through scheduled workshop-led sessions (typically twice per month), mentoring engagements, and market activities. Companies should ensure that at least one designated representative maintains continuity throughout the programme to maximise value and maintain strategic alignment
The programme is delivered as Team UK:
- British Chambers of Commerce – national coordination and programme design
- BritChamSingapore – in market delivery and matchmaking
- NatWest – SME capability building and financial readiness
- UK government partners – diplomatic alignment
- Specialist partners – evolving programmeexpertise
The cost of the accelerator is £5000 + VAT per business. This is not inclusive of travel and accommodation costs which must be covered by the business.
This is not an application fee – an invoice will only be raised at the time of acceptance onto the cohort. Many of our partners will offer a level of free support or 1-2-1 sessions in addition to the main training modules. Should businesses wish to engage with those partners for further support costs will be negotiated directly and are not associated with the Trade Accelerator.
You submit a short Expression of Interest and then the full application form to be submitted. Alternatively, businesses may submit the application form straight away,
If shortlisted, you will receive onboarding materials and join the cohort kick off in London.
While it is possible that participating companies may operate in related areas, the cohort will be carefully curated to minimise direct overlap in products and market positioning wherever possible.
All accepted participants will be required to adhere to a code of conduct and confidentiality agreement to ensure open and constructive engagement. The programme is designed as a peer-learning environment, and we encourage companies to benefit from shared insights, even where business models or technologies are adjacent.
Our objective is to foster collaboration, knowledge exchange, and collective growth, while maintaining appropriate safeguards for commercially sensitive information.